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ABSTRACT: Antibody−drug conjugates are an important
class of cancer therapeutics. These agents generally bind a
specific cell surface receptor, undergo receptor-mediated
endocytosis, and enter the endosomal−lysosomal system,
where the environment in these organelles facilitates the
release of a membrane-permeable cytotoxin. By using a
membrane-impermeable cytotoxin, we describe here a method
that allows the cytotoxicity of an antibody conjugate to be
triggered by co-administration with an endosome-disruptive
peptide that exhibits low toxicity. This approach was validated by conjugation of an anionic derivative of the tubulin-binding
cytotoxin colchinol methyl ether to lysine residues of the HER2-targeting antibody trastuzumab (Herceptin) via a disulfide.
When this antibody binds HER2 on SKBR3 breast cancer cells and undergoes endocytosis, the membrane-impermeable
cytotoxin is released, but it becomes trapped in endosomes, resulting in relatively low cytotoxicity (IC50 > 1 μM). However, co-
administration with an essentially nontoxic (IC50 > 10 μM) cholesterol-linked endosome-disruptive peptide promotes the
release of this small molecule into the cytoplasm, conferring subnanomolar cytotoxic potency (IC50 = 0.11 ± 0.07 nM). Studies
of a structurally related fluorophore conjugate revealed that the endosome-disruptive peptide does not substantially enhance
cleavage of the disulfide (t1/2 = 8 ± 2 h) within endosomes, suggesting that the mechanism of endosomal escape involves the
efflux of some small molecules without facilitating substantial influx of reduced glutathione.
■ INTRODUCTION
Antibody−drug conjugates (ADCs) are under extensive
development as targeted therapeutics.1 The approval by the
FDA and EMA of Adcetris (brentuximab vedotin, targeting
CD30 in Hodgkin lymphoma)2 and Kadcyla (ado-trastuzumab
emtansine, targeting HER2 in breast cancer)3 has catalyzed
numerous basic and clinical studies of a wide range of next-
generation conjugates, with particular emphasis on oncology.1
Most antibody−cytotoxin conjugates bind internalizing cell
surface receptors that cycle between the plasma membrane and
endosomes, providing a mechanism for delivery of agents into
these acidic intracellular compartments. The dissociation from
receptors in endosomes and fusion of endosomes with
lysosomes exposes these conjugates to more highly hydrolytic
and acidic environments where proteases and other enzymes
can facilitate cleavage of linkers between the protein and
cytotoxin. Liberated small molecules generally diffuse across
membranes of endosomes or lysosomes and manifest
cytotoxicity by engaging targets in the cytoplasm or nucleus
of cells.
Effective ADCs must exhibit sufficient stability to reach
targeted cells but also be labile enough to release small-
molecule cargo at the target site. To attain this profile, a variety
of linker structures, including acid-labile hydrazones,4−6
noncleavable thioethers that require extensive antibody
proteolysis for release,7−10 specific protease substrates,11−13
and disulfides,14−17 have been investigated. However,
variations in the rates of cleavage of these linkers in different
cell types may affect efficacy and off-target toxicity. Addition-
ally, ADCs may exhibit undesired toxicity by binding cognate
antigens on nontarget cells, through uptake by nontarget cells
that express Fc receptors, or via premature release of toxins
that diffuse from targeted cells into neighboring cells.18 This
premature release is of greatest concern when the toxin is
highly cell-permeable. In contrast, less cell-permeable toxins
may exhibit fewer side effects,19−21 but restricting the ability to
cross membranes can also reduce engagement of intracellular
targets responsible for cytotoxicity. To better control the
activities of ADCs, chemical strategies for triggering the release
of drugs from antibodies are under investigation.22,23
One approach that has been used to promote the release of
cargo into the cytoplasm of mammalian cells involves the
disruption of intracellular endosomes. Both natural and
synthetic agents have been used to promote the escape of
entrapped molecules from these membrane-sealed compart-
ments.24−26 This approach has been used for the delivery of
nucleic acids,27,28 fluorophores,29,30 and targeted immunotox-
ins31 into the cytosol. We previously reported32 the synthesis
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of a cholesterylamine-linked peptide that selectively disrupts
membranes of early and recycling endosomes. This peptide
was used to release a disulfide derivative of fluorescein,
delivered into endosomes by conjugation to a cholesteryl-
amine, into the cytoplasm and nucleus. Here, we describe the
use of this approach to release cell-impermeable small
molecules from endosomes delivered as conjugates of the
antibody trastuzumab (Herceptin). Trastuzumab was partic-
ularly attractive for this strategy because when this anticancer
antibody binds its target protein HER2 on the surface of breast
cancer cells, it rapidly undergoes receptor-mediated endocy-
tosis, but upon delivery to early/recycling endosomes, it is
predominantly recycled back to the cell surface, and only a
small fraction traffics to the lysosome.33 Some other anticancer
antibodies such as rituximab34 are less likely to synergize with
endosome-disruptive peptides because they are not rapidly
internalized upon binding cognate cell surface antigens. As
shown in Figure 1, we reasoned that the cytotoxicity of an
impermeable cytotoxin warhead delivered as a trastuzumab
conjugate might be triggered by an endosome-disruptive
peptide, limiting the effects of the cytotoxin on nontargeted
cells. Using a cell-impermeable derivative of the cytotoxin
colchinol methyl ether (iCME) linked to trastuzumab and an
optimized cholesterol-linked endosome-disruptive peptide
(Chol-EDP), we demonstrate that these two agents show
low cytotoxicity individually, but when combined, potently kill
HER2-positive SKBR3 cells, while sparing HER2-negative
MDA-MB-468 cells.
■ RESULTS AND DISCUSSION
Design and Synthesis. To validate the concept that a
small molecule delivered by an antibody can be released by co-
administration with an endosome-disruptive lipopeptide, we
designed fluorescein disulfide conjugates of the HER2-targeted
antibody trastuzumab (1) and human IgG (2) as a nontargeted
control (Figure 2). We additionally designed a novel
endosome-disruptive peptide termed here Chol-EDP (3,
Figure 2) that is structurally related to our previously
reported32 cholesterylamine-modified PC4 peptide.35 Chol-
EDP (3) differs from cholesterylamine-PC4 in its cholesteryl
carbamate membrane anchor, the incorporation of solubility-
enhancing ethylene glycol-containing amino acids (O), and
conformationally constraining Aib (U) residues known to
promote helix formation,36 and it adds three additional amino
acids in the aromatic-rich region to better complement the
36−43 Å thickness37 of membranes of mammalian cells. The
comparison of the structures of these peptides is shown in the
Supporting Information (Figure S1).
We further designed targeted trastuzumab and nontargeted
hIgG antibody conjugates (4, 5) bearing an anionic (poorly
cell permeable) derivative of the tubulin-binding cytotoxin
colchinol methyl ether (iCME, Figure 3). These lysine
conjugates include a linker containing β-alanines, a glutamic
acid residue to limit cell permeability of the small molecule, a
disulfide amino acid, and a lysine modified with Pacific Blue
(PB),38 a fluorescent probe that was used for both detection
and quantification of the degree of antibody labeling (DOL).
Colchinol methyl ether (CME) is an analogue of the plant
natural product colchicine. This natural product inhibits
mitosis by binding tubulin,39 and it has been previously
investigated40,41 linked to tumor-targeted cytotoxins. In CME,
the tropone ring of colchicine is contracted to form a benzene.
This modification increases potency for inhibition of tubulin
and decreases off-target effects.42,43 A trastuzumab conjugate
that substitutes CME with the comparably hydrophobic
Pennsylvania Green (PG)44,45 fluorophore (6) was designed
as a structurally related mechanistic probe. Analogues of CME
designed to be cell-permeable (7) and cell-impermeable (8)
were designed as positive (7) and negative (8) control
compounds.
Synthesis of the 5-carboxyfluorescein-disulfide-NHS ester
used to prepare antibody conjugates 1 and 2 is described in the
Experimental Section. The synthesis of more complex NHS
esters used to generate antibody conjugates 4−6 is shown in
Figure 4. Deacetylcolchinol methyl ether (11) was synthesized
as previously reported.46,47 Antibody conjugates 1, 2 and 4−6
were prepared by random modification of lysine residues with
Figure 1. Strategy for activation of an antibody−cytotoxin conjugate
(trastuzumab−iCME) by an endosome-disruptive peptide (Chol-
EDP). Trastuzumab−iCME alone was designed to be essentially
nontoxic (panel A) as a result of low membrane permeability of the
linked colchinol methyl ether derivative (iCME). Chol-EDP was
designed to similarly exhibit low toxicity (panel B). In combination,
Chol-EDP triggers the release of the iCME warhead into the
cytoplasm (panel C), resulting in toxicity.
Figure 2. Structures of disulfide-linked antibody−fluorescein
conjugates (1, 2, panel A) and a novel cholesterol-linked endo-
some-disruptive peptide (3, panel B). In panel B, letters in bold either
represent natural L-amino acids or are defined as specific non-
proteogenic amino acids.
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NHS esters, purified by size-exclusion chromatography, and
the DOL was quantified by absorbance spectroscopy, as
described in the Experimental Section. Chol-EDP (3) was
prepared by solid-phase peptide synthesis, as described in the
Experimental Section.
Biological Evaluation. We previously demonstrated that
cholesterylamine-PC4 can disrupt endosomes of Jurkat
lymphocyte cells (EC50 (14 h) = 1.3 ± 0.3 μM) and release
HS-fluorescein from these compartments when cells are
treated with cholesterylamine-SS-fluorescein (structures and
data shown in Figure S1, Supporting Information).32 The
comparison of cholesterylamine-PC4 with the novel analogue
Chol-EDP (3) by flow cytometry revealed that 3 is ∼30-fold
more potent (EC50 (14 h) = 0.04 ± 0.01 μM) as a disruptor of
endosomes but maintains comparably low cytotoxicity (IC50
(3, 48 h) = 11 ± 2 μM) toward Jurkat cells (Figure S1).
Because of its enhanced potency, we used Chol-EDP (3) to
investigate effects on the HER2-targeted and nontargeted
fluorescent antibody conjugates 1 and 2. As shown in Figure 5,
treatment of HER2-expressing SKBR3 cells with these
conjugates, and imaging by confocal laser-scanning micros-
copy, revealed that trastuzumab-Fl (1) binds with high affinity
Figure 3. Structures of antibody−cytotoxin conjugates (4, 5, panel
A), a blue/green fluorescent trastuzumab conjugate (6 panel B), and
control compounds (7, 8, panel C).
Figure 4. Synthesis of NHS esters used to prepare lysine-linked
antibody conjugates 4−6.
Figure 5. DIC and confocal fluorescence micrographs of living
HER2+ SKBR3 cells treated with HER2-targeted (1) and nontargeted
(2) fluorescent antibody conjugates (1 μM) without (A, C) and with
(B, D) Chol-EDP (3, 2 μM) for 24 h. DOL(1) = 4.6. DOL(2) = 4.5.
Scale bar = 25 μm.
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and specificity to cellular plasma membranes and accumulates
in intracellular compartments. Previous studies of related
fluorescent trastuzumab conjugates in SKBR3 cells have
revealed a very similar pattern of cellular and subcellular
localization, where the intracellular compartments co-localize
with the early endosomal marker transferrin.33 Co-admin-
istration of 1 with Chol-EDP (3) for 24 h resulted in
fluorescence dispersed throughout cells, a phenotype asso-
ciated with the cleavage of the disulfide of 1, and escape of HS-
fluorescein from endosomes into the cytosol and nucleus. In
contrast, the nontargeted hIgG-Fl (2) conferred much lower
levels of cellular fluorescence in the absence and presence of 3
(Figure 5, compare A and C). However, the small amount of
compartmentalized intracellular fluorescence observed with
hIgG-Fl (2), presumably the result of some uptake by
pinocytosis, was similarly dispersed throughout the cytoplasm
and nucleus upon treatment with 3 (Figure 5, compare C and
D). Similar studies of trastuzumab-Fl (1) in the HER2-
negative breast cancer cell line MDA-MB-468 revealed low
cellular fluorescence, consistent with the low expression of
HER2 in this cell line, comparable to that observed with hIgG-
Fl (2) in SKBR3 cells (Figure S2).
To determine whether antibody−iCME conjugates (4, 5)
might synergize with Chol-EDP (3), we evaluated effects on
cellular viability. We reasoned that when the targeted
conjugate 4 binds HER2 on the cell surface and undergoes
endocytosis, the impermeability of the released HS-iCME (8)
product would cause its entrapment in endosomes and
lysosomes, rendering it essentially nontoxic. However, co-
administration with Chol-EDP (3) could release 8 into the
cytosol, where it could bind tubulin and block cell division.
The Pacific Blue fluorophore on the protein side of the
disulfide linker was used to quantify the average number of
small molecules per antibody (degree of labeling, DOL),
confirm the extent of binding to cells by confocal microscopy,
and evaluate cellular uptake by flow cytometry (Figure S3).
To quantify cellular cytotoxicity, dose−response curves for
combinations of 3, 4, and 5 were generated with HER2-
positive SKBR3 cells and HER2-negative MDA-MB-468 cells
after treatment for 72 h (Figure 6). As a positive cytotoxic
control, cells were treated with N-acetylcolchinol methyl ether
(7). As a cell-impermeable negative control, the anionic CME
derivative 8, predicted to result from cleavage of the disulfide
of 4 and 5 (Figure 4) was evaluated. Under these conditions,
cell-permeable 7 was highly toxic toward both cell lines (IC50
(SKBR3) = 7 ± 5 nM; IC50 (MDA-MB-468) = 14 ± 8 nM). In
contrast, the anionic CME derivative 8 was essentially nontoxic
(IC50 > 10 μM), consistent with low cellular permeability. As
expected, the nontargeted hIgG conjugate 5 exhibited
relatively low toxicity alone (IC50 (SKBR3) > 1 μM) toward
either cell line. When this nontargeted conjugate (5) was
combined with the essentially nontoxic Chol-EDP (3, IC50
(SKBR3) > 10 μM), held at a fixed nontoxic concentration of
2 μM, this combination was also of relatively low toxicity (IC50
(SKBR3) ∼ 700 nM), despite the likelihood of some uptake of
this conjugate by pinocytosis. Under these same conditions,
the cytotoxicity of 8 was not substantially enhanced by co-
administration with 2 μM of Chol-EDP (IC50 (SKBR3) ∼ 7
μM; IC50 (MDA-MB-468) > 10 μM, data not shown).
Similarly, the HER2-targeted trastuzumab conjugate 4
exhibited relatively low toxicity alone (IC50 (SKBR3) > 1
μM) toward HER2-positive SKBR3 cells and lower toxicity
toward HER2-negative MDA-MB-468 cells (IC50 (MDA-MB-
468) > 10 μM). In contrast, when SKBR3 cells were treated
with a combination of the HER2-targeted conjugate 4 and
Chol-EDP (3, 2 μM), this combination synergistically killed
more than 90% of cells in culture with subnanomolar potency
(IC50 (SKBR3) = 0.11 ± 0.07 nM), while maintaining
relatively low toxicity toward MDA-MB-468 cells under
identical conditions (IC50 (MDA-MB-468) > 1 μM).
Consequently, Chol-EDP (3) enhanced the toxicity of the
targeted trastuzumab-iCME (4) toward HER2+ SKBR3 cells
by ∼10 000-fold, but it did not comparably enhance the
toxicity of 4 toward HER2− MDA-MB-468 cells under the
same conditions. An additional analysis of the cellular
fluorescence emitted by Pacific Blue of trastuzumab-iCME
(4) in the absence of Chol-EDP (3) revealed subnanomolar
potency of antibody uptake by SKBR3 cells (EC50 = 0.5 ± 0.2
nM, Figure S3), further confirming potent binding to the
HER2 antigen by this conjugate, despite its low cytotoxicity
alone. In conjunction with the microscopy studies of 1−3
(Figure 5), these results support a mechanism of targeted
synergistic cytotoxicity involving binding of the trastuzumab−
iCME conjugate 4 to HER2 on SKBR3 cells, endocytosis, and
release of HS-iCME (8) from endosomes mediated by Chol-
EDP (3).
The mechanism of disruption of endosomes by Chol-EDP
(3) is not fully understood. However, based on previous
studies of structurally related fluorescent cholesteryl carba-
mates48 and cholesterylamine-PC4,32 the insertion of the
cholesterol moiety of this compound into cellular plasma
Figure 6. Quantification of cytotoxic IC50 values (±SEM) toward
SKBR3 cells (A) and MDA-MB-468 cells (B). Cells were treated with
3−5 and controls 7−8 for 72 h and cytotoxicity was analyzed by flow
cytometry. DOL(4) = 5.9. DOL(5) = 5.7.
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membranes is likely to allow it to engage an endocytic
trafficking pathway that leads to its predominant accumulation
in early and recycling endosomes. We hypothesize that the
hydrophobic peptide moiety of Chol-EDP (3) may addition-
ally insert into endosomal membranes to form pores that allow
the escape of small molecules from these compartments, but
further studies will be necessary to more precisely define its
mechanism of action. To gain greater insight into the effect of
Chol-EDP (3) on disulfide-linked antibody conjugates, we
investigated effects on the trastuzumab−PB−PG conjugate 6.
This conjugate is structurally very similar to 4 but it substitutes
CME with Pennsylvania Green (PG),44,45 a highly fluorescent
small molecule of comparable molecular size and hydro-
phobicity. Importantly, like other coumarin-fluorescein
pairs,49,50 fluorescence spectroscopy revealed that the proximal
PB fluorophore of 6 undergoes Förster resonance energy
transfer (FRET) with PG, providing a new FRET pair that
allows cleavage of the disulfide bond between these
fluorophores to be followed. When 6 was treated with the
reducing agent dithiothreitol (DTT) in aqueous buffer,
decreased FRET between these fluorophores and reduced
fluorescence quenching resulted in enhanced blue and green
fluorescence (data shown in Figure S4). A similar increase in
blue fluorescence was also observed as the disulfide of 4 was
cleaved, from decreased fluorescence quenching of PB by
iCME (Figure S4). These effects on fluorescence allowed
quantification of the half-lives associated with the cleavage of
the disulfide under pseudo-first-order conditions (t1/2 (6) =
307 ± 24 s; t1/2 (4) = 274 ± 26 s). These studies demonstrated
that the kinetics of cleavage of the disulfides of 6 and 4 are
similar in aqueous buffer, but 6 additionally allows observation
of the release of the green fluorescent probe as a mimic of
iCME.
Confocal microscopy and flow cytometry were used to
analyze the time-dependent fluorescence of SKBR3 cells
treated with the targeted FRET conjugate 6 in the absence
and presence of 3 (Figure 7). Immediately after addition of 6,
this conjugate can be observed bound to the plasma
membrane. Over time, fluorescence accumulates intracellularly
as this conjugate is endocytosed, where it presumably
additionally returns to the cell surface via plasma membrane
recycling. Confocal micrographs showed that green fluores-
cence is only released from endosomes upon treatment with
both 6 and 3; cells treated with only 6 showed exclusively
compartmentalized green fluorescence, consistent with intact
endosomal membranes (Figure 7). However, unlike the
smaller HS-fluorescein moiety of 1, the green fluorescent
HS-Glu-PG moiety of 6 is not as extensively trapped in the
cytoplasm and nucleus upon disruption of endosomes. We
hypothesize that differential interactions with efflux trans-
porters might explain this difference in cellular retention.
These studies further revealed that 3 has some effects on the
subcellular trafficking of 6. In the absence of 3, 6 is located
mostly at the cell surface with minimal accumulation in
endosomes. This is consistent with previously reported
extensive endosomal recycling of HER2 back to the plasma
membrane.51,52 Co-treatment of 6 with 3 leads to greater
accumulation of 6 within acidic intracellular compartments,
presumably endosomes and lysosomes, that co-localize with
LysoTracker Red DND-99 (Figure S5). The mechanism
underlying this increased trafficking of the antibody conjugate
to intracellular compartments is unknown, but it may enhance
the release of cargo from these acidic compartments.
To quantify the rate of cleavage of the disulfide of 6 in
endosomes, and the impact of treatment with 3, we
synthesized trastuzumab−PB−SH as a positive control for
complete cleavage of the disulfide. To prepare this control,
conjugate 6 was treated with excess DTT. The trastuzumab−
PB−SH product was purified by size-exclusion chromatog-
raphy to remove HS-PG and DTT, and the loss of green
fluorescence and increased blue fluorescence was confirmed by
fluorescence spectroscopy (data not shown). The analysis of a
related trastuzumab−PB conjugate by flow cytometry under
the same conditions demonstrated that this treatment did not
adversely affect potency for HER2 on SKBR3 cells, but binding
efficacy was reduced by ∼17% (Figure S4), and this difference
was factored into the analysis of the kinetics of disulfide
Figure 7. (A−C) Confocal micrographs of living SKBR3 cells treated
with trastuzumab−PB−PG (6, 1 μM, DOL = 2.6). In panel A, cells
were treated at 4 °C for 0.5 h prior to washing and imaging. Panels B
and C: Cells were treated at 4 °C for 0.5 h prior to washing and
incubation at 37 °C for 56 h in the absence (B) and presence (C) of
Chol-EDP (3, 2 μM). In panel C, white arrows illustrate cells with
dispersed green fluorescence resulting from endosome disruption and
increased localization of blue and green fluorescence in endosomes/
lysosomes. Scale bar = 25 μm. (D) Analysis of the kinetics of cleavage
of the disulfide of 6 (DOL = 2.6) by flow cytometry. The half-time of
cleavage of the disulfide of 6 and the extent of cleavage (±SEM) are
not significantly altered by co-administration with 3.
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cleavage in cells. Cells treated with trastuzumab−PB−SH were
compared with cells treated with 6 in the absence and presence
of 3 to measure the half-time of the cleavage reaction. These
studies revealed that Chol-EDP (3) does not significantly
affect the cleavage of 6 in endosomes (t1/2 (6) = 8 ± 2 h; t1/2
(6 + 3) = 7 ± 2 h). The similarity of these values suggests that
despite facilitating the efflux of small molecules from
endosomes, 3 does not promote substantial influx of cytosolic
GSH into endosomes to promote disulfide cleavage. A similar
6 h half-life of a folate receptor-targeted FRET probe in KB
cells was previously reported by Low and co-workers.53 We
found that the disulfide of 6 is maximally cleaved by ∼30% in
endosomes, and this cleavage did not increase appreciably from
24 to 72 h. When endosomes were pre-permeabilized by
treatment with 3 for 24 h prior to addition of 6, similar results
were obtained (data not shown), further indicating a lack of
association between the cleavage of the disulfide bond and
endosome disruption. This partial cleavage is consistent with
another report54 describing less than 50% cleavage when
HER2-positive breast cancer cells are treated with trastuzumab
emtansine disulfide for 20 h. Additionally, when maytansine
DM1 is conjugated to IgG via disulfide-containing linkers, this
drug is cleaved from the antibody with half-lives of 15−218 h,
depending on the extent of a steric hindrance about the
disulfide bond.17,55 Other studies of trastuzumab conjugates
have indicated that recycling endosomes, late endosomes, and
lysosomes are oxidizing in SKBR3 cells, and cleavage of
disulfides can be inefficient.56 Consequently, subtle structural
elements are likely to play a major role in the cleavage of
disulfide linkers within the endosomal pathway. Other HER2-
targeted antibody conjugates cleaved by cathepsin proteases
have been shown by FRET to be cleaved by 41% after 20 h in
SKBR3 cells.51
■ CONCLUSIONS
We report a remarkable cytotoxic synergy between a cell-
impermeable antibody−drug conjugate and an endosome-
disruptive peptide. The trastuzumab−iCME conjugate 4
(cytotoxic IC50 (SKBR3, 72 h) > 1 μM) and endosome-
disruptive peptide Chol-EDP (3, cytotoxic IC50 (SKBR3, 72 h)
> 10 μM) exhibit relatively low toxicity individually, but when
combined potently kill more than 90% of targeted cancer cells
that express HER2 (cytotoxic IC50 (SKBR3, 72 h) = 0.11 ±
0.07 nM). Mechanistic studies of a structurally related green
fluorescent antibody conjugate support a mechanism of
synergy involving binding of these trastuzumab conjugates to
HER2 on cell surfaces, receptor-mediated endocytosis, and
cleavage of the disulfide bond in the lumen of endosomes, with
a half-life of 8 ± 2 h. When the trastuzumab−iCME conjugate
4 is added alone, cleavage of the disulfide in endosomes yields
a membrane-impermeable thiol (HS-iCME, 8) that remains
trapped in the lumen, limiting cytotoxicity. However, when
cells are treated with Chol-EDP (3), this lipopeptide initially
associates with the cellular plasma membrane but subsequently
traffics to endosomes, where it appears to slowly permeabilize
endosomal membranes (studies of the release of fluorescence
from conjugate 1 mediated by 3 indicate that substantial
endosomal escape requires >8 h). This permeabilization of
endosomal membranes by Chol-EDP (3) enables the release of
the highly polar HS-iCME (8), delivered by trastuzumab-
iCME (4), from endosomes into the cytoplasm and nucleus,
allowing 8 to disrupt microtubules and block cell division.
The low toxicity of Chol-EDP (3) suggests that this peptide
may create small pores in endosomal membranes that do not
adversely affect cellular viability. However, if this mechanism is
operational, these pores must be sufficiently large to allow the
escape of HS-fluorescein and HS-iCME (8) from endosomes
into the cytoplasm. Surprisingly, studies of the structurally
similar FRET probe 6 revealed that Chol-EDP (3) does not
affect the cleavage of the disulfide of 4, suggesting that this
compound does not appear to trigger massive influx of reduced
glutathione (GSH), present in high concentrations (0.5−10
mM)57 in the cytosol, into endosomes. Because endosomes
and lysosomes have been reported to be oxidizing,56 thiol
reductases58 in these compartments presumably mediate
cleavage of disulfides. Products of proteolytic cleavage and
disulfide reduction have been previously detected in cells
treated with antibody−disulfide conjugates,54 and proteolysis
could potentially also contribute to this release of cargo. We
found that Chol-EDP (3) additionally affects the trafficking
and subcellular localization of trastuzumab conjugates by
increasing their accumulation in acidic intracellular compart-
ments, and this altered trafficking may play a role in enhancing
endosomal escape.
Given the recent interest22,23 in triggering the release of
small molecules from antibodies and previous studies of
delivery of toxins using endosome-disruptive agents,31 the
approach described here has the potential to improve the
properties of ADCs. Cell-impermeable toxins that can be
activated by other nontoxic compounds may reduce side
effects associated with premature release and diffusion of toxins
into nontargeted cells. Alternatively, pretargeting, involving
treatment and wash-out of the ADC followed by subsequent
administration of an endosome-disruptive peptide, might
improve the therapeutic index of some of these types of agents.
■ EXPERIMENTAL SECTION
General Experimental Section. Chemical reagents were
purchased from Aapptec, Acros, Aldrich, Alfa Aesar, EMD
Biosciences, or TCI America and were used without further
purification. Solvents were from Aldrich or Fisher Scientific. 3-
((((Cholester-3-yl)oxy)carbonyl)amino)propanoic acid,59 3-
((2-(((9H-fluoren-9-ylmethoxy)carbonyl)amino)ethyl)-
dithio)propanoic acid,32,60 and Pacific Blue NHS ester (PB-
NHS)61 were prepared as previously described. Analytical
reverse-phase (RP) HPLC employed an Agilent 1220 Series
binary pump and an Agilent PLRP-S RP analytical column (8
μm particle size, 4 mm × 25 cm) with diode-array detection at
254 nm. Preparative RP-HPLC employed an Agilent 1200 or
1260 Series preparative pump/gradient extension with a
Hamilton PRP-1 (polystyrene-divinylbenzene) RP preparative
column (10−12 μm particle size, 21.5 mm × 25 cm, flow rate
of 25.0 or 16.0 mL/min with a gradient (0.1% TFA) of H2O/
MeCN, 9:1 (1 min) to 0:100 (24 min), 0:100 (5 min), 9:1 (5
min)). HPLC fractions containing water were dried using a
Labconco FreeZone 4.5 lyophilizer. Compounds containing
basic amines were isolated as TFA salts. Nuclear magnetic
resonance (NMR) spectra were recorded on a 500 MHz
Bruker Avance spectrometer with a dual carbon/proton
cryoprobe. Chemical shifts are reported in parts per million
(ppm) and are referenced to the center line of the solvent
(DMSO-d6:
1H, 2.50 ppm, 13C 39.51 ppm). Coupling
constants are given in Hertz (Hz). Spin multiplicities are
reported as s = singlet, d = doublet, t = triplet, q = quartet, dd
= doublet of doublet, td = doublet of triplet, and m = multiplet.
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SPPS was performed on a Mettler Toledo MiniBlock reactor
(model no: Bohdan 2080 on a 12-well block with glass reaction
vessels, 600 rpm) utilizing standard Fmoc chemistry.
Synthetic Procedures and Compound Character-
ization Data. ((3β-Cholest-5-en-3-yl)carbonyl)-β-alanyl-β-
alanyl-L-glutamyl-L-glutamyl-mPEG-mPEG-aminoisobutyl-
aminoisobutyl-aminoisobutyl-aminoisobutyl-L-tryptophyl-L-
tyrosyl-L-alanyl-L-tryptophyl-L-tyrosyl-L-alanyl-L-tryptophyl-
L-tyrosyl-L-prolyl-L-prolyl-L-valyl-L-valinamide (Chol-EDP, 3).
SPPS was performed on Rink amide MBHA resin (0.5 mmol/
g, 40 mg, 0.02 mmol) swelled in DMF for 2 h. The removal of
the Fmoc group was accomplished by agitating with the
deblocking solution (20% piperidine in DMF, 2 mL, 2×, for 4
min each). The resin was washed with DMF (2 mL, 4×) to
remove any traces of piperidine and treated with Fmoc-amino
acids (4 equiv), HATU (3.8 equiv), and DIEA (8 equiv) in
DMF (2 mL) with agitation until coupling was complete by
Kaiser Test (3, 6, 12, or 16 h). Once the coupling was
complete, the reaction solution was drained, and the resin was
washed four times with DMF (2 mL). This coupling protocol
was repeated for each additional Fmoc-amino acid. The
hindered 2-aminoisobutyric acid (Aib) was coupled as the acid
fluoride (Fmoc-Aib-F), synthesized using DAST.62 Fmoc-Aib-
F (4 equiv) was dissolved in DMF (0.5 mL), added to the
resin, and agitated for 6 h. Coupling to 3-((((cholester-3-
yl)oxy)carbonyl)amino)propanoic acid,59 cleavage with TFA/
H2O/TIPS (95/2.5/2.5) with agitation for 2 h, and
purification by RP-HPLC provided 3 as a white solid (15
mg, 0.005 mmol, 24% overall yield). LRMS (ESI−) m/z calcd
for C164H232N26O37 [(M − 2H)/2]−: 1578.3, found: 1578.8.
5-((2-((3-((2,5-Dioxopyrrolidin-1-yl)oxy)-3-oxopropyl)-
disulfanyl)ethyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanth-
en-9-yl)benzoic Acid (This Compound is Also Termed Here
5-Carboxyfluorescein-disulfide-NHS Ester). 3-((2-(((9H-Flu-
oren-9-ylmethoxy)carbonyl)amino)ethyl)dithio)propanoic
acid32,60 (28 mg, 0.070 mmol) was dissolved in DMF (1 mL)
containing 20% piperidine and stirred at 22 °C for 30 min. The
solvent was removed under vacuum to provide the primary
amine. 5-Carboxyfluorescein NHS ester (17 mg, 0.035 mmol)
dissolved in dry DMF (2 mL) was added. DIEA (0.2 mL) was
added, and the reaction was stirred at 22 °C for 16 h. The
solvent was removed under vacuum, the residue was dissolved
in CH2Cl2 containing 5% methanol, applied to a short silica
plug, and eluted with CH2Cl2/MeOH (9:1). The solvent was
removed under vacuum to give the crude carboxylic acid. This
product (∼15 mg) was dissolved in DMF (2 mL), and EDC
(11 mg, 0.06 mmol), N-hydroxysuccinimide (7 mg, 0.06
mmol) were added. The reaction was stirred at 22 °C for 16 h.
The solvent was removed under vacuum, the residue was
dissolved in DMSO (2 mL), and the product was purified by
preparative RP-HPLC. Pure fractions were collected, com-
bined, and dried under vacuum to give 5-carboxyfluorescein-
disulfide-NHS ester (9 mg, 0.014 mmol, 39% overall yield) as a
yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 9.01 (t, J = 5.5
Hz, 1H), 8.46 (s, 1H), 8.25 (d, J = 7.9, 1.6 Hz, 1H), 7.38 (d, J
= 8.0 Hz, 1H), 6.69 (d, J = 1.9 Hz, 2H), 6.59 (d, J = 8.6 Hz,
2H), 6.56−6.53 (m, 2H), 3.62 (q, J = 6.3 Hz, 2H), 3.13 (t, J =
6.5 Hz, 2H), 3.05 (t, J = 6.9 Hz, 2H), 2.98 (t, J = 6.6 Hz, 2H),
2.54 (s, 4H). 13C NMR (126 MHz, DMSO-d6) δ 170.1, 168.2,
167.5, 164.8, 159.6, 154.7, 151.8, 136.0, 134.7, 129.2, 126.5,
124.3, 123.3, 112.7, 109.1, 102.3, 40.4, 36.9, 31.9, 30.4, 25.4.
HRMS (ESI+) m/z calcd for C30H24N2O10S2 [M + Na]
+:
659.0765, found: 659.0740.
(4S)-4-(3-Mercaptopropanamido)-5-oxo-5-((3-oxo-3-((3-
oxo-3-(((5R)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-
dibenzo[a,c][7]annulen-5-yl)amino)propyl)amino)propyl)-
amino)pentanoic Acid (HS-iCME, 8). Disulfide 18 (6 mg,
0.004 mmol) was dissolved in DMSO (0.4 mL). DL-
Dithiothreitol (DTT, 13 mg, 0.085 mmol) was added, and
the solution was stirred at room temperature (22 °C) for 16 h.
The crude mixture was purified by RP-HPLC and lyophilized
to yield HS-iCME (8) as a white solid (2 mg, 68% yield). 1H
NMR (500 MHz, DMSO-d6) δ 8.39 (d, J = 8.4 Hz, 1H), 8.10
(d, J = 8.0 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H), 7.89 (dt, J = 10.9,
5.8 Hz, 2H), 7.24 (d, J = 8.1 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H),
6.77 (s, 1H), 4.57−4.48 (m, 1H), 4.0 (td, J = 8.4, 5.4 Hz, 1H),
3.82 (s, 3H), 3.78 (s, 3H), 3.77 (s, 3H), 3.47, (s, 3H), 3.30−
3.12 (m, 4H), 2.95−2.85 (m, 1H), 2.78−2.68 (m, 1H), 2.68−
2.60 (m, 1H), 2.49−2.41 (m, 2H), 2.37−2.28 (m, 2H), 2.24−
2.13 (m, 4H), 2.10−1.99 (m, 1H), 1.88 (d, J = 6.1 Hz, 2H),
1.77−1.63 (m, 2H), 1.30−1.21 (m, 1H). 13C NMR (126 MHz,
DMSO) δ 173.9, 171.2, 170.4, 170.3, 169.6, 158.4, 152.1,
150.3, 141.8, 140.6, 134.8, 130.5, 126.1, 124.3, 110.8, 109.3
108.0, 60.5, 55.8, 54.9, 51.9, 48.2, 40.0, 39.9, 39.7, 39.5, 39.3,
39.2, 39.0, 38.3, 35.4, 35.3, 35.3, 35.1, 30.2, 30.2, 27.4, 25.2,
19.9. HRMS (ESI+) m/z calcd for C33H44N4O10S [M + H]
+:
689.2856, found: 689.2849.
(10S,25S)-10-((((9H-Fluoren-9-yl)methoxy)carbonyl)-
amino)-25-(3-(tert-butoxy)-3-oxopropyl)-2,2-dimethyl-
4,11,15,23,26-pentaoxo-3-oxa-19,20-dithia-5,12,16,24,27-
pentaazatriacontan-30-oic Acid (9). 2-Chlorotrityl chloride
resin (2-CTC, Aapptec, RTZ001, 0.1 mmol) was allowed to
swell in CH2Cl2 (10 min). The first Fmoc-L-amino acid (4 eq)
in dry CH2Cl2 (4 mL) containing DIEA (8 eq) was added to
the MiniBlock reactor with agitation for 16 h. The resin was
washed with CH2Cl2 (4 mL, 4×) followed by MeOH (4 mL)
with agitation (10 min) to cap any unreacted resin. The
solvent was removed, and the resin was washed with DMF (4
mL, 4×). Additional coupling steps were performed as
described for the preparation of 3 on Rink amide resin, with
the exception of the disulfide amino acid, which was added as
the acid fluoride. Briefly, Fmoc-protected 3-((2-aminoethyl)-
disulfanyl)propanoic acid (80 mg, 0.2 mmol) was dissolved in
dry CH2Cl2 (2 mL) in a polypropylene conical tube (15 mL).
Drops of dry DMF were added until the solution cleared,
followed by the addition of DAST (63 μL, 0.48 mmol). The
reaction was stirred for 30 min at 4 °C and was quenched by
the addition of ice water. The organic layer was washed with
satd. aqueous NaCl and dried over anhydrous Na2SO4. The
crude material was concentrated under reduced pressure and
redissolved in DMF. The resulting solution was immediately
added to the resin with agitation for 16 h. Cleavage of 9 from
2-CTC resin was accomplished by treatment with CH2Cl2/
TFE/acetic acid (7:2:1, 4 mL) with shaking for 3 h. The resin
was removed by filtration and washed with CH2Cl2 (2 mL, 3×)
and DMF (2 mL, 3×). The filtrates were combined and
concentrated under vacuum to give crude products.
Purification by RP-HPLC yielded 9 as a white solid (34 mg,
35% yield). 1H NMR (500 MHz, DMSO-d6) 12.23 (brs, 1H),
8.09 (d, J = 8.1 Hz, 1H), 8.05 (t, J = 5.7 Hz, 1H), 7.94 (t, J =
5.6 Hz, 1H), 7.89 (d, J = 7.4 Hz, 3H), 7.72 (t, J = 6.5 Hz, 2H),
7.42 (t, J = 7.4 Hz, 3H), 7.33 (t, J = 7.5 Hz, 2H), 6.75 (t, J =
5.9 Hz, 1H), 4.31−4.18 (m, 5H), 3.93−3.84 (m, 2H), 3.35−
3.17 (m, 6H), 2.93−2.83 (m, 4H), 2.75 (t, J = 6.9 Hz, 2H),
2.54 (q, J = 4.0, 3.1 Hz, 2H), 2.37 (t, J = 6.9 Hz, 2H), 2.24 (t, J
= 7.0 Hz, 2H), 2.22−2.15 (m, 2H), 1.88−1.80 (m, 1H), 1.72−
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1.63 (m, 1H), 1.61−1.52 (m, 2H), 1.37 (s, 9H), 1.36 (s, 9H),
1.27−1.16 (m, 1H). 13C NMR (126 MHz, DMSO) δ 172.8,
171.9, 171.6, 171.0, 170.4, 170.1, 155.9, 155.6, 143.9, 143.8,
140.7, 127.6, 127.1, 125.3, 120.1, 79.7, 77.3, 65.6, 54.7, 51.7,
46.7, 40.0, 39.8, 39.7, 39.5, 39.3, 39.2, 39.0, 37.9, 37.1, 35.2,
35.2, 34.9, 34.8, 33.9, 33.7, 31.7, 31.3, 29.2, 283, 27.7, 27.45
22.9. MS (ESI+) m/z calcd for C46H66N6O12S2 [M + H]
+:
959.4258, found: 959.4267.
(10S,25S)-10-((((9H-Fluoren-9-yl)methoxy)carbonyl)-
amino)-25-(3-(tert-butoxy)-3-oxopropyl)-2,2-dimethyl-
4 , 11 , 1 5 , 23 , 2 6 , 30 -hexaoxo -3 -oxa -19 , 20 -d i t h i a -
5,12,16,24,27,31-hexaazatetratriacontan-34-oic Acid (10).
Using 2-chlorotrityl resin (0.1 mmol) and the coupling
conditions and building blocks described for 9, the crude
mixture was purified by RP-HPLC and lyophilized to provide
10 as a white solid (50 mg, 49% yield). 1H NMR (500 MHz,
DMSO-d6) 12.20 (brs, 1H), 8.15−8.00 (m, 2H), 7.96−7.84
(m, 5H), 7.73 (t, J = 6.5 Hz, 2H), 7.42 (t, J = 7.3 Hz, 3H),
7.33 (t, J = 7.7 Hz, 2H), 6.76 (t, J = 5.9 Hz, 1H), 4.34−4.13
(m, 5H), 3.97−3.81 (m, 2H), 3.47−3.11 (m, 8H), 3.00−2.81
(m, 4H), 2.75 (t, J = 6.9 Hz, 2H), 2.56−2.51 (m, 2H), 2.36 (t,
J = 7.1 Hz, 2H), 2.30−2.11 (m, 6H), 1.93−1.76 (m, 1H),
1.76−1.62 (m, 1H), 1.62−1.43 (m, 2H), 1.37 (s, 9H), 1.36 (s,
9H), 1.29−1.15 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ
172.9, 171.9, 171.6, 170.9, 170.4, 170.3, 170.1, 155.9, 155.5,
143.9, 143.8, 140.7, 127.6, 127.0, 125.3, 120.1, 79.6, 77.3, 65.6,
54.7, 51.8, 46.7, 37.9, 37.1, 35.3, 35.2, 35.2, 35.0, 34.9, 34.7,
33.9, 33.8, 31.7, 31.3, 29.2, 28.3, 27.7, 27.5, 22.8. LRMS (ESI
+) m/z calcd for C49H71N7O13S2 [M + H]
+: 1030.5, found:
1030.5.
tert-Butyl (2-(4-(2,7-Difluoro-6-hydroxy-3-oxo-3H-xanth-
en-9-yl)-3-methylbenzamido)ethyl)carbamate (12). To a
solution of 4-carboxy Pennsylvania Green succinimidyl ester
(95 mg, 0.2 mmol), prepared as previously reported,45,63 in
DMF (1 mL) were added DIEA (125 μL, 0.5 mmol) and N-
Boc-ethylenediamine (47 μL, 0.3 mmol). The reaction mixture
was stirred at 22 °C for 4 h. Solvents were removed under
reduced pressure followed by purification by silica gel
chromatography (eluent: CH2Cl2/MeOH (15:1) with 1%
acetic acid) to afford 12 (78 mg, 75%) as an orange solid. 1H
NMR (500 MHz, DMSO-d6) δ 8.60 (t, J = 5.7 Hz, 1H), 7.96
(s, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H),
6.92 (t, J = 5.8 Hz, 1H), 6.84 (d, J = 6.6 Hz, 2H), 6.61 (d, J =
11.1 Hz, 2H), 3.34 (q, J = 6.2 Hz, 2H), 3.15 (q, J = 6.3 Hz,
2H), 2.08 (s, 3H), 1.38 (s, 9H). 13C NMR (126 MHz, DMSO-
d6) δ 165.83, 155.78, 149.38, 149.33, 149.28, 135.93, 135.75,
134.27, 129.53, 129.02, 125.13, 111.35, 105.15, 105.12, 77.69,
40.42, 28.22, 19.08. HRMS (ESI−) m/z calcd for
C28H25F2N2O6 [M-H]
−: 523.1681, found: 523.1668.
tert-Butyl-(10S,25S)-10-((((9H-fluoren-9-yl)methoxy)-
carbonyl)amino)-2,2-dimethyl-4,11,15,23-tetraoxo-25-((3-
oxo-3-((3-oxo-3-(((5R)-3,9,10,11-tetramethoxy-6,7-dihydro-
5H-dibenzo[a,c][7]annulen-5-yl)amino)propyl)amino)-
propyl)carbamoyl)-3-oxa-19,20-dithia-5,12,16,24-tetraa-
zaoctacosan-28-oate (14). To a solution of 10 (40 mg, 0.039
mmol) in dry DMF (2 mL) were added HATU (30 mg, 0.078
mmol), DIEA (35 μL, 0.19 mmol), and CME (11, 26 mg,
0.078 mmol). The mixture was stirred overnight and
concentrated under reduced pressure. The crude material
was purified by RP-HPLC and lyophilized to afford 14 as a
white solid (38 mg, 73% yield). 1H NMR (500 MHz, DMSO-
d6) 8.39 (d, J = 8.4 Hz, 1H), 8.13−8.00 (m, 2H), 7.94−7.84
(m, 5H), 7.72 (t, J = 6.6 Hz, 2H), 7.45−7.36 (m, 3H), 7.32 (t,
J = 7.5 Hz, 2H), 7.24 (d, J = 8.1 Hz, 1H), 6.90−6.83 (m, 2H),
6.81−6.69 (m, 2H), 4.52 (dt, J = 11.9, 7.6 Hz, 1H), 4.35−4.15
(m, 5H), 3.95−3.84 (m, 2H), 3.82 (s, 3H), 3.77 (s, 3H), 3.77
(s, 3H), 3.47 (s, 3H), 3.34−3.15 (m, 8H), 2.88 (tt, J = 6.9, 4.4
Hz, 4H), 2.75 (t, J = 7.0 Hz, 2H), 2.59−2.52 (m, 2H), 2.48−
2.45 (m, 1H), 2.39−2.27 (m, 2H), 2.27−2.09 (m, 7H), 2.09−
1.98 (m, 1H), 1.91−1.76 (m, 2H), 1.72−1.62 (m, 1H), 1.61−
1.43 (m, 2H), 1.36 (s, 9H), 1.36 (s, 9H), 1.29−1.14 (m, 2H).
13C NMR (126 MHz, DMSO-d6) δ 171.9, 171.3, 170.9, 170.4,
170.2, 170.1, 169.6, 158.4, 155.9, 152.1, 150.3, 143.9, 143.8,
141.8, 140.7, 140.6, 134.7, 130.5, 127.6, 127.1, 126.1, 125.3,
124.3, 120.1, 110.8, 109.3, 108.1, 79.7, 77.3, 65.6, 60.5, 55.8,
54.9, 54.7, 51.8, 48.2, 46.7, 38.3, 37.9, 37.1, 35.4, 35.3, 35.3,
35.2, 35.2, 35.1, 34.9, 33.9, 31.7, 31.3, 30.1, 29.2, 28.3, 27.7,
27.5, 22.9. LRMS (ESI+) m/z calcd for C68H92N8O16S2 [M +
H]+: 1341.6, found: 1341.7.
tert-Butyl (10S,25S)-10-((((9H-Fluoren-9-yl)methoxy)-
carbonyl)amino)-25-((3-((2-(4-(2,7-difluoro-6-hydroxy-3-
oxo-3H-xanthen-9-yl)-3-methylbenzamido)ethyl)amino)-3-
oxopropyl)carbamoyl)-2,2-dimethyl-4,11,15,23-tetraoxo-3-
oxa-19,20-dithia-5,12,16,24-tetraazaoctacosan-28-oate
(15). To a solution of 9 (34 mg, 0.035 mmol) in dry DMF (1
mL) were added HATU (27 mg, 0.071 mmol) and DIEA (33
μL, 0.18 mmol). Separately, 12 (37 mg, 0.071 mmol) was
treated with TFA/CH2Cl2 (0.5 mL, 1:1) for 30 min. The
mixture was concentrated under reduced pressure and washed
with CH2Cl2 (2 mL, 4×) to remove excess TFA and afford 13
as the crude amine. This crude amine was dissolved in dry
DMF (0.5 mL) and added to the solution of HATU-activated
carboxylic acid. The mixture was stirred for 16 h, and the
solvent was removed with a Biotage V-10 Touch. Purification
by RP-HPLC followed by lyophilization afforded 15 as an
orange solid (17 mg, 36% yield). 1H NMR (500 MHz, DMSO-
d6) δ 8.67 (t, J = 5.7 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.07−
8.00 (m, 3H), 7.98−7.86 (m, 7H), 7.72 (t, J = 6.5 Hz, 2H),
7.45−7.35 (m, 4H), 7.32 (t, J = 7.7 Hz, 2H), 6.85 (d, J = 7.0
Hz, 2H), 6.75 (t, J = 5.2 Hz, 1H), 6.61 (d, J = 11.1 Hz, 2H),
4.31−4.13 (m, 5H), 3.89 (p, J = 7.2 Hz, 1H), 3.40−3.17 (m,
10H), 2.93−2.82 (m, 4H), 2.74 (t, J = 6.9 Hz, 1H), 2.59−2.51
(m, 1H), 2.34−2.12 (m, 6H), 2.08 (s, 3H), 1.88−1.79 (m,
1H), 1.75−1.64 (m, 1H), 1.62−1.47 (m, 2H), 1.36 (s, 9H),
1.35 (s, 9H), 1.27−1.21 (m, 2H). 13C NMR (126 MHz,
DMSO-d6) δ 171.9, 171.6, 171.1, 171.0, 170.6, 170.6, 170.4,
170.2, 165.9, 158.4, 158.1, 157.8, 155.9, 155.6, 143.9, 143.8,
140.7, 136.0, 135.7, 134.3, 129.6, 129.1, 127.6, 127.1, 125.3,
125.1, 120.1, 116.6, 114.3, 105.1, 79.6, 77.3, 65.6, 54.7, 51.8,
46.7, 40.0, 39.8, 39.7, 39.5, 39.3, 39.2, 39.0, 38.3, 37.9, 37.1,
35.4, 35.3, 35.2, 34.9, 33.9, 33.3, 31.7, 31.3, 31.3, 29.2, 28.3,
27.7, 27.5, 22.9, 19.10. LRMS (ESI+) m/z calcd for
C69H82F2N8O15S2 [M + H]
+: 1365.5, found: 1365.5.
(5S,20S)-5-(4-(6,8-Difluoro-7-hydroxy-2-oxo-2H-chro-
mene-3-carboxamido)butyl)-1-(9H-fluoren-9-yl)-3,6,10,18-
tetraoxo-20-((3-oxo-3-((3-oxo-3-(((5R)-3,9,10,11-tetrame-
thoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)amino)-
propyl)amino)propyl)carbamoyl)-2-oxa-14,15-dithia-
4,7,11,19-tetraazatricosan-23-oic Acid (16). 14 (30 mg,
0.022 mmol) was dissolved in TFA/CH2Cl2 (1:3, 2 mL) and
stirred for 2 h. The solvent was removed under reduced
pressure, and the solid was dissolved in dry DMF (2 mL).
Pacific Blue NHS ester (PB-NHS, 11 mg, 0.034 mmol) and
DIEA (8 μL, 0.045 mmol) were added. The solution was
stirred for 16 h, and the solvent was removed under reduced
pressure. The crude material was purified by RP-HPLC and
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lyophilized to afford 16 as a yellow solid (21 mg, 67% yield).
1H NMR (500 MHz, DMSO-d6) 12.08 (brs, 1H), 8.75 (s,
1H), 8.59 (t, J = 5.8 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.09 (d,
J = 8.1 Hz, 1H), 8.04 (t, J = 5.7 Hz, 1H), 7.97−7.88 (m, 3H),
7.85 (dd, J = 7.6, 3.8 Hz, 2H), 7.70 (t, J = 7.8 Hz, 3H), 7.45 (d,
J = 8.3 Hz, 1H), 7.42−7.36 (m, 2H), 7.35−7.27 (m, 2H), 7.24
(d, J = 8.2 Hz, 1H), 6.90−6.83 (m, 2H), 6.76 (s, 1H), 4.57−
4.48 (m, 1H), 4.35−4.26 (m, 1H), 4.23−4.12 (m, 4H), 3.96−
3.89 (m, 1H), 3.82 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 3.47 (s,
3H), 3.34−3.14 (m, 10H), 2.94−2.81 (m, 2H), 2.79−2.70 (m,
2H), 2.56−2.51 (m, 2H), 2.48−2.43 (m, 1H), 2.39−2.28 (m,
2H), 2.27−2.10 (m, 7H), 2.09−1.98 (m, 1H), 1.92−1.80 (m,
2H), 1.74−1.58 (m, 2H), 1.58−1.44 (m, 3H), 1.40−1.25 (m,
2H). 13C NMR (126 MHz, DMSO-d6) δ 173.9, 171.9, 171.0,
170.4, 170.3, 170.1, 169.6, 160.9, 159.6, 158.4, 158.3, 158.0,
157.77, 157.5, 155.9, 152.1, 150.3, 147.9, 147.1, 143.8, 141.8,
140.7, 140.6, 140.5, 134.7, 130.5, 127.6, 127.6, 127.0, 126.1,
125.34, 125.3, 124.3, 120.1, 117.7, 116.4, 110.8, 110.5, 110.4,
109.6, 109.4, 109.3, 108.1, 65.6, 60.5, 55.8, 54.9, 54.5, 51.9,
48.2, 46.7, 38.3, 37.9, 37.1, 35.4, 35.3, 35.3, 35.2, 35.1, 34.9,
33.9, 31.7, 30.2, 30.1, 28.7, 27.5, 23.0. LRMS (ESI+) m/z calcd
for C69H78F2N8O18S2 [M + H]
+: 1409.5, found: 1409.5.
(5S,20S)-20-((3-((2-(4-(2,7-Difluoro-6-hydroxy-3-oxo-3H-
xanthen-9-yl)-3-methylbenzamido)ethyl)amino)-3-
oxopropyl)carbamoyl)-5-(4-(6,8-difluoro-7-hydroxy-2-oxo-
2H-chromene-3-carboxamido)butyl)-1-(9H-fluoren-9-yl)-
3,6,10,18-tetraoxo-2-oxa-14,15-dithia-4,7,11,19-tetraazatri-
cosan-23-oic Acid (17). 15 (17 mg, 0.012 mmol) was
dissolved in TFA/CH2Cl2 (1:3, 2 mL) and stirred for 2 h.
The solvent was removed under reduced pressure, and the
residue was washed with CH2Cl2 to remove all traces of acid (2
mL, 3×). The product was dissolved in dry DMF (1.5 mL),
and PB-NHS (9 mg, 0.029 mmol) and DIEA (14 μL, 0.080
mmol) were added. The solution was stirred for 16 h, and the
solvent was removed with a Biotage V-10 Touch. The crude
product was purified by RP-HPLC to afford 17 as a yellow
solid (6 mg, 34% yield). 1H NMR (500 MHz, DMSO-d6) δ
8.74 (s, 1H), 8.67 (t, J = 5.6 Hz, 1H), 8.58 (t, J = 5.8, 5.3 Hz,
1H), 8.11 (d, J = 8.0 Hz, 1H), 8.04 (q, J = 6.0 Hz, 2H), 7.98−
7.90 (m, 3H), 7.89 (d, J = 8.1 Hz, 1H), 7.86−7.82 (m, 2H),
7.73−7.66 (m, 3H), 7.44 (d, J = 8.2 Hz, 1H), 7.41−7.35 (m,
3H), 7.30 (q, J = 6.9 Hz, 2H), 6.84 (s, 1H), 6.61 (d, J = 11.1
Hz, 2H), 4.33−4.25 (m, 1H), 4.24−4.12 (m, 4H), 3.96−3.88
(m, 2H), 3.36 (q, J = 6.3 Hz, 2H), 3.32−3.28 (m, 4H), 3.26−
3.20 (m, 4H), 2.90−2.84 (m, 4H), 2.74 (t, J = 6.5 Hz, 2H),
2.56−2.52 (m, 2H), 2.29−2.17 (m, 6H), 2.08 (s, 3H), 1.93−
1.79 (m, 1H), 1.78−1.66 (m, 1H), 1.65−1.58 (m, 1H), 1.57−
1.45 (m, 3H), 1.39−1.20 (m, 3H). LRMS (ESI+) m/z calcd
for C70H68F4N8O17S2 [M + H]
+: 1433.4, found: 1433.4.
(7S,22S)-1-(6,8-Difluoro-7-hydroxy-2-oxo-2H-chromen-3-
yl)-7-(5-((2,5-dioxopyrrolidin-1-yl)oxy)-5-oxopentanamido)-
1,8,12,20-tetraoxo-22-((3-oxo-3-((3-oxo-3-(((5R)-3,9,10,11-
tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)-
amino)propyl)amino)propyl)carbamoyl)-16,17-dithia-
2,9,13,21-tetraazapentacosan-25-oic Acid (18). 16 (15 mg,
0.011mmol) was dissolved in diethylamine/DMF (1:4, 1 mL)
and stirred for 1 h. After complete cleavage of the Fmoc
protecting group confirmed by mass spectral analysis, the
solvent was removed under reduced pressure. The crude
material was dissolved in DMF, and disuccinimidyl glutarate
(35 mg, 0.11 mmol) and DIEA (19 μL, 0.11 mmol) were
added. The solution was stirred for 16 h, and solvents removed
under reduced pressure. The crude material was purified by
RP-HPLC and lyophilized to afford 18 as a light yellow solid
(7 mg, 47% yield). 1H NMR (500 MHz, DMSO-d6) 12.07
(brs, 1H), 8.78 (d, J = 1.3 Hz, 1H), 8.58 (t, J = 5.8 Hz, 1H),
8.39 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.1 Hz, 1H), 8.04 (t, J =
5.7 Hz, 1H), 7.99−7.83 (m, 4H), 7.75 (dd, J = 10.4, 2.0 Hz,
1H), 7.24 (d, J = 8.1 Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.76
(s, 1H), 4.60−4.46 (m, 1H), 4.29−4.10 (m, 3H), 3.82 (s, 3H),
3.78 (s, 3H), 3.77 (s, 3H), 3.47 (s, 3H), 3.35−3.14 (m, 11H),
2.92−2.84 (m, 2H), 2.80 (s, 2H), 2.75 (t, J = 6.9 Hz, 2H), 2.67
(t, J = 7.5 Hz, 1H), 2.54 (s, 4H), 2.49−2.44 (m, 1H), 2.39−
2.29 (m, 2H), 2.27−2.10 (m, 8H), 2.07−1.99 (m, 1H), 1.92−
1.78 (m, 3H), 1.74−1.57 (m, 2H), 1.56−1.43 (m, 3H), 1.37−
1.19 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 173.9,
171.7, 171.1, 170.9, 170.4, 170.2, 170.2, 170.2, 170.1, 169.6,
168.7, 160.9, 159.6, 158.4, 158.1, 157.8, 152.1, 150.3, 147.1,
141.8, 140.5, 134.7, 130.5, 126.1, 124.3, 117.5, 116.5, 110.8,
108.1, 99.5, 60.5, 55.8, 54.9, 52.4, 51.9, 48.2, 40.4, 38.3, 37.9,
37.1, 35.4, 35.3, 35.3, 35.2, 35.1, 34.90, 33.8, 33.5, 31.7, 31.4,
30.1, 30.07, 29.6, 28.7, 27.5, 25.4, 22.9, 20.4. LRMS (ESI+) m/
z calcd for C63H77F2N9O21S2 [M + H]
+: 1398.5, found: 1398.5.
(7S,22S)-22-((3-((2-(4-(2,7-Difluoro-6-hydroxy-3-oxo-3H-
xanthen-9-yl)-3-methylbenzamido)ethyl)amino)-3-
oxopropyl)carbamoyl)-1-(6,8-difluoro-7-hydroxy-2-oxo-2H-
chromen-3-yl)-7-(5-((2,5-dioxopyrrolidin-1-yl)oxy)-5-oxo-
pentanamido)-1,8,12,20-tetraoxo-16,17-dithia-2,9,13,21-
tetraazapentacosan-25-oic Acid (19). 17 (6 mg, 0.004
mmol) was dissolved in diethylamine/DMF (1:4, 1 mL) and
stirred for 1 h. After complete cleavage of the Fmoc protecting
group confirmed by mass spectral analysis, the solvent was
removed with a Biotage V-10 Touch. The crude material was
dissolved in DMF (0.45 mL), and disuccinimidyl glutarate (14
mg, 0.04 mmol) and DIEA (7 μL, 0.04 mmol) were added.
The solution was stirred for 16 h. The crude product was
diluted with DMSO (0.45 mL), purified by RP-HPLC, and
lyophilized to afford 19 as a yellow solid (4 mg, 67% yield). 1H
NMR (500 MHz, DMSO-d6) δ 12.07 (brs, 1H), 8.77 (s, 1H),
8.67 (t, J = 6.3 Hz, 1H), 8.57 (t, J = 5.6 Hz, 1H), 8.11 (d, J =
8.1 Hz, 1H), 8.04 (q, J = 5.2 Hz, 2H), 7.98−7.86 (m, 4H),
7.74 (dd, J = 10.6, 2.1 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 6.85
(brs, 1H), 6.61 (d, J = 11.0 Hz, 2H), 4.25−4.12 (m, 2H),
3.33−3.15 (m, 12H), 2.88 (t, J = 7.3 Hz, 2H), 2.81 (d, J = 4.3
Hz, 4H), 2.77−2.72 (m, 2H), 2.71−2.64 (m, 1H), 2.59 (s,
2H), 2.54 (s, 2H), 2.40 (t, J = 7.3 Hz, 2H), 2.30−2.17 (m,
8H), 2.14 (t, J = 7.4 Hz, 1H), 2.08 (s, 3H), 1.89−1.77 (m,
2H), 1.74−1.65 (m, 2H), 1.52−1.45 (m, 2H), 1.31−1.21 (m,
3H). LRMS (ESI+) m/z calcd for C64H67F4N9O20S2 [M +
Na]+: 1422.4, found: 1422.4.
Biological Assays and Protocols. SKBR3 breast cancer
cells (ATCC HTB-30) were cultured in complete media
comprising DMEM Nutrient Mixture F-12 Ham (Sigma
Aldrich, D8437) supplemented with fetal bovine serum
(10%, Hyclone-characterized FBS, SH3039603), penicillin
(100 units/mL, Sigma Aldrich P4333), and streptomycin
(100 μg/mL, Sigma Aldrich P4333). MDA-MB-468 breast
cancer cells (ATCC HTB-132, a kind gift of Dr. Liang Xu)
were cultured in complete media comprising DMEM (Sigma
Aldrich, D6429) supplemented with fetal bovine serum (10%,
Hyclone-characterized FBS, SH3039603), penicillin (100
units/mL, Sigma Aldrich P4333), and streptomycin (100 μg/
mL, Sigma Aldrich P4333). All cells were grown in T75 flasks
(CytoOne CC7682-4875) and incubated at 37 °C with 5%
CO2.
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Confocal Microscopy. Imaging was performed using an
inverted Leica TCS SPE confocal laser-scanning microscope
fitted with a Leica 63× oil-immersion objective. Fluorescent
probes were excited with either a 405 or 488 nm solid-state
laser, and emitted photons were collected from 425 to 500 or
500 to 600 nm. Unless otherwise noted, laser power and PMT
gain settings were identical for all images acquired within a
given experiment to allow accurate comparisons of cellular
fluorescence.
Flow Cytometry. A Beckman Coulter Cytoflex S (B2-R0-
V2-Y2) flow cytometer was used for cellular analysis. Cells
were excited with 405 and/or 488 nm diode lasers, and emitted
photons were collected through 450/45 BP (Pacific Blue),
525/40 BP (Pennsylvania Green), or 690/50 nm BP (PI)
filters. FSC threshold was set to 500 000, flow speed was fast,
mixing and backflush times were 5 s.
Fluorescence Spectroscopy. Fluorescence spectra were
recorded using a PerkinElmer LS-55 fluorescence spectrom-
eter. Samples were excited at 405 or 488 nm, and emission was
recorded from 425 to 700 or 515 to 700 nm with a scan speed
of 500 nm/min and slit width of 10 nm. Samples were analyzed
in a SUPRASIL macro/semimicro cell (PerkinElmer,
B0631132)
Labeling of Antibodies with NHS Esters. Trastuzumab,
obtained from a hospital pharmacy, was provided as a
lyophilized powder mixed 1:1 with stabilizers (α,α-trehalose
dihydrate, L-histidine, and polysorbate 20). Human IgG was
provided as a lyophilized powder without stabilizers (Sigma,
I4506). Trastuzumab was reconstituted in sterile PBS (pH 7.4)
and passed through a spin column packed with Sephadex G-25
to remove the stabilizers. Briefly, Sephadex G-25 resin
(Superfine, Sigma, S5772) was suspended in PBS (pH 7.4).
The resulting slurry (950 μL) was added to a minispin column
(USA Scientific, 1415-0600) and centrifuged (16 000g, 20 s) to
remove the buffer and pack the resin. The antibody solution
(no more than 75 μL per column) was loaded onto the packed
resin and centrifuged (16 000g, 30 s) to separate the protein
from the stabilizers. The concentration of trastuzumab was
determined by absorbance at 280 nm using a Nanodrop 1000
instrument (IgG ε1% (10 mg/mL) = 13.7 L g
−1 cm−1). The
concentration was adjusted to 100 μM using sterile PBS. IgG
was reconstituted in sterile PBS (pH 7.4) and the
concentration determined and adjusted as described above.
To label antibodies with NHS esters, the IgG in PBS (100
μM, 25−300 μL) was aliquoted into a 1.5 mL microcentrifuge
tube. NaHCO3 (aq., 1 M) was added (2.5−30 μL) to achieve a
final concentration of 0.1 M. NHS esters were added as
concentrated (typically 10 mM) DMSO stock solutions to
achieve 5- to 10-fold excess over the antibody concentration.
Solutions were incubated in a Big Shot III Hybridization oven
(0.5 h, 37 °C). To purify the conjugates, Sephadex G-25 resin
was packed into columns, as described above. The antibody
solution was loaded onto the packed resin (no more than 75
μL per column) and centrifuged (16 000g, 30 s) to separate the
protein from unconjugated small molecules. This was done
twice to ensure full removal of toxins and larger fluorophores;
once was sufficient for small fluorophores. Conjugates used for
toxicity assays or other 72 h assays were additionally sterilized
by passage through Ultra-MC centrifugal filters (0.22 μm,
Millipore, UFC30GV0S) by centrifugation (13 000g, 3 min).
After purification, the degree of labeling (DOL) of each
conjugate was determined by absorbance spectroscopy.
Absorbance values at 280 and 425 or 488 nm (IgG, 280 nm
ε1% (10 mg/mL) = 13.7 L g
−1 cm−1, Pacific Blue, 425 nm ε = 29
500 M−1 cm−1, Fluorescein, 490 nm ε = 70 000 M−1 cm−1,
Pennsylvania Green, 490 nm ε = 60 000 M−1 cm−1) were
measured with a Nanodrop 1000 Spectrophotometer to
quantify the average number of molecules per antibody.
From the absorbance of 18 at 280 nm (4:1 DMSO/PBS),
CME contributes an additional 30% of the absorbance of PB at
280 nm, and the concentrations and DOL of 4 and 5 were
corrected64 to account for this contribution.
Visualization of Endosome Disruption by Confocal
Microscopy. Cells were seeded in complete media into 8-well
μ-slides (Ibidi, 80826, 100 000 cells/mL, 300 μL/well) and
allowed to adhere overnight. Each well was washed once with
media, and then the media was replaced with complete media
(150 μL) containing vehicle control (0.1% DMSO),
fluorescent conjugate, and/or EDP at the indicated concen-
tration. The concentrations of all DMSO stock solutions were
normalized using extinction coefficients and UV−vis spectros-
copy. Cells were incubated for 24 h, washed once with media,
and imaged by confocal microscopy.
Analysis of Cytotoxicity. SKBR3 and MDA-MB-468 cells
were used to analyze the toxicity of antibody−toxin conjugates.
Cells were plated in the appropriate complete media into
CytoOne 96-well tissue culture plates (USA Scientific,
CC7682-7596) at 50 000 cells/mL (200 μL/well) and
incubated for 16 h. On the same day, IgG and trastuzumab
(50 μL each) were labeled with 18 (10-fold excess), as
described above, to yield 4 at 50 μM (DOL = 5.9) and 5 at 53
μM (DOL = 5.7). The next day, DMSO stock solutions of N-
acetylcolchinol methyl ether (7, 1 mM, ε = 20 000 M−1 cm−1
at 262 nm in EtOH), Chol-EDP (3, 10 mM, ε = 20 970 M−1
cm−1 at 280 nm in 4:1 DMSO/PBS), and HS-iCME (8, 10
mM, ε for 7 was used) were prepared and standardized by
absorbance using molar extinction coefficients. These com-
pounds were serially diluted 1:3 to yield 1000× DMSO stock
solutions (0.3−300 μM for 7, 10−10 000 μM for 3 and 8).
These solutions were diluted 1:1000 into complete media to
yield final concentrations of 0.3−300 nM for 7 and 10−10 000
nM for 3 and 8 (Final [DMSO] = 0.1%). Media was aspirated
from each well and replaced with this treated media (150 μL)
in triplicate. Antibody conjugates were serially diluted in the
appropriate complete media to yield solutions ranging from
0.03 to 1000 nM. Each sample was split into two equal
aliquots, yielding two sets of samples for each conjugate. Chol-
EDP (3, from a 2 mM DMSO stock solution) was added to
one set of each conjugate so cells could be co-treated with the
antibody conjugate and Chol-EDP. Media was aspirated from
each well and replaced with the treated media (150 μL) in
triplicate. After incubation for 72 h, the media was aspirated
from each well, and each well was washed with PBS (100 μL).
Cells were trypsinized by addition of 50 μL of trypsin to each
well and incubation at 37 °C for 10 min. Trypsin was
quenched with media (150 μL) containing propidium iodide
(PI, 3 μM from a 3 mM PBS stock solution, Thermo Fisher
Scientific, P1304MP), and cells in each well were pipetted
repeatedly to break up clumps. Plates were immediately
analyzed using a Beckman Coulter Cytoflex S (B2-R0-V2-Y2)
flow cytometer. Cells were collected for 20 s per well. Other
settings are described under Flow Cytometry. Light scattering
and staining with PI were used to identify populations of living
cells. Counts of viable cells for each treatment, determined in
triplicate, were used to generate dose−response curves. These
curves were fitted by nonlinear regression with an inhibitor vs
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response 3-parameter model (GraphPad Prism 8) to determine
IC50 values.
Analysis of SKBR3 Cells Treated with 6 by Confocal
Microscopy as a Function of Time. SKBR3 cells were
plated in complete media onto 8-well μ-slides (Ibidi, 80826,
125 000 cells/mL, 300 μL/well) and allowed to adhere for 16
h. Each well was washed once with media. The media was
replaced with complete media (100 μL) containing antibody
conjugate 6 (1 μM) with or without 3 (2 μM). Additional
controls shown in Figures S1 and S2 used cholesterylamine-SS-
fluorescein32 (250 nM) as a fluorescent probe to further
confirm the endosome-disruptive activity of 3 in a given set of
experiments. Cells were incubated at 4 °C for 0.5 h. Cells were
washed twice with media (with the exception of cells treated
with cholesterylamine-SS-fluorescein,32 which diffuses away
over time), and the media was replaced with media (300 μL),
containing 3 (2 μM) where appropriate. Cells were
immediately imaged as described in Confocal Microscopy for
the t = 0 time point. Cells were incubated at 37 °C prior to
imaging for all other time points.
Analysis of SKBR3 Cells Treated with 6 by Flow
Cytometry as a Function of Time. SKBR3 cells were plated
in complete media into CytoOne 96-well tissue culture plates
(USA Scientific, CC7682-7596) at 75 000 cells/mL (200 μL/
well) and incubated overnight (16 h). On the same day,
trastuzumab (300 μL) was labeled with 19 (4-fold excess) as
described above to yield 6 at 62 μM (DOL = 2.6). As a fully
cleaved control, trastuzumab−PB−SH was prepared from 6 by
the addition of DTT (1 mM) to 6 followed by incubation (37
°C) in a Big Shot III Hybridization Oven (2 h). Fluorescence
emission was monitored, and the reaction was allowed to
proceed until the fluorescence stopped increasing (Figure S6).
The solution was purified using Sephadex G-25 and filter
sterilized as described above to yield trastuzumab−PB−SH (58
μM, DOL = 2.0). Trastuzumab (75 μL each) was additionally
labeled on lysines with only Pennsylvania Green NHS ester or
Pacific Blue NHS ester (2-fold excess of each) to produce
trastuzumab-PG (70 μM, DOL 1.5) and trastuzumab−PB (62
μM, DOL 1.7) as additional controls to assure spectral
orthogonality in both confocal microscopy and flow cytometry
experiments (data not shown).
The next day, sufficient antibody conjugate (1 μM) in media
was prepared with and without 3 (2 μM) to dose wells in
triplicate (100 μL) and obtain 8 time points. Media was also
prepared with Cholesterylamine-SS-Fluorescein32 (250 nM)
with and without 3 (2 μM) as a positive control to confirm
endosome disruption by 3 (data not shown). The media was
aspirated from the wells and replaced with this treated media
(100 μL) in triplicate. Cells were incubated at 4 °C for 0.5 h.
Cells were then washed once with media, and the media was
replaced with media (200 μL), containing 3 (2 μM) where
appropriate. Wells corresponding to time point t = 0 were
immediately trypsinized as described in Analysis of Cytotox-
icity, with the exception that PI was not added. Cells were
analyzed as described in Flow Cytometry. Cells were incubated
at 37 °C until the next time point.
To determine the half-life of the release of the Pennsylvania
Green derivative from 6, median blue fluorescence values from
each well were collected. The values of 6 with and without 3
were multiplied by 0.83 to correct for the lower efficacy of
binding of trastuzumab−PB for HER2 after treatment with
DTT compared to 6. These values were divided by the
corresponding values of trastuzumab−PB−SH (as a control for
complete cleavage of 6) with and without 3. These ratios were
then normalized using the value at t = 0 as representative of 0%
cleavage and a ratio of one as representative of 100% cleavage.
The half-life was determined by curve fitting using a one-phase
association model (GraphPad Prism 8). The normalized ratios
of each time point with and without 3 were compared using
unpaired t tests (one per time point) with the assumption that
all data were sampled from populations with the same scatter
using the Holm−Sidak method (α = 5%). The differences in
half-lives with and without 3 were not significant.
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Pacific Blue fluorophore; PG, Pennsylvania Green fluorophore;
PMT, photomultiplier tube; BP, bandpass filter; PBS,
phosphate buffered saline (pH 7.4); ED, ethylenediamine
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